Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Trophos Program Boosted by EUR 1 Million Grant for Olesoxime in Progressive MS

Published: Friday, October 12, 2012
Last Updated: Friday, October 12, 2012
Bookmark and Share
Agence Nationale de la Recherche awards second grant to Trophos led consortium for Phase Ib/IIa clinical study.

Trophos SA has announced the award of a EUR 1 million grant to support the Translate-MS-Repair project.

The French 'Agence Nationale de la Recherche' (ANR) awarded the second successive grant to Trophos to target Multiple Sclerosis with olesoxime.

The funding will be provided under the Recherches Partenariales et Innovation Biomedicale 2012 program.

Translate-MS-Repair will be a 24 month project and will include a Phase Ib/IIa clinical study of olesoxime, Trophos' lead compound, to target neurodegeneration that underlies long term progressive disability in multiple sclerosis.

The project will be operated by a consortium spearheaded by Trophos including leading experts in Marseille (AP-HM/CNRS and CEMEREM-CRMBM), Rennes (CHU de Rennes and INRIA VISAGES) and Reims (CHU de Reims).

The clinical trial, which will be performed in 3 centers in France, will be led by Dr. Jean Pelletier AP-HM/CNRS-CEMEREM.

The clinical trial is designed to demonstrate the compatibility of olesoxime as a co-medication with existing treatments, the most frequent being beta interferon.

The study will also assess the feasibility of non-conventional magnetic resonance imaging procedures in a multicenter trial.

The clinical trial is designed to result in future large-scale clinical trials to assess efficacy of olesoxime to prevent progressive disability in MS patients.

"MS is the first cause of non-traumatic disability in young adults. While there are a number of effective treatments to control the relapsing inflammatory episodes, they have little effect on progressive disability in MS patients," said Rebecca Pruss, CSO, Trophos.

Pruss continued, "MS is a chronic inflammatory disease leading to demyelination and axonal degeneration in the central nervous system. However, it is now also recognized that MS is a neuro-degenerative disease as well. There is a real unmet need for agents to promote neuroprotection and myelin repair for MS."

"The second grant from the ANR to Trophos for our MS program is a recognition of the quality of Trophos' ongoing activity in neurodegenerative diseases within the Trophos pipeline," said Christine Placet, CEO, Trophos. "The ongoing success of olesoxime and the Trophos pipeline fits perfectly with Trophos strategy value creation."

Translate-MS-Repair is a sequel to the successful ANR funded MS-Repair project lead by Trophos and performed in collaboration with Aix-Marseille University and CNRS partners, IBDML (UMR 6216) and CRMBM (UMR 6612).

MS-Repair (ANR-08-BIOT-016-01) explored from 2008 to 2011 the activity of the molecule olesoxime in various in vitro and in vivo models of MS.

This project showed that the molecule is not only neuroprotective, but it has the ability to promote the maturation of oligodendrocyte progenitor cells (OPCs) into myelinating oligodendrocytes (details in Magalon et al, Ann Neurol. 2012 Feb;71(2):213-26).

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Trophos Announces Top-Line Results in Pivotal Trial of Olesoxime in SMA
Promising results for the maintenance of motor function in spinal muscular atrophy - a rare, serious and debilitating pediatric-onset neurodegenerative disease.
Thursday, March 20, 2014
Trophos Completes Pivotal Phase II/III Study of Olesoxime in SMA
The French patients’ association AFM-Telethon supported the study which evaluates the ability of olesoxime to preserve the neuromuscular function of SMA patients.
Friday, November 08, 2013
Trophos Announces Final Patient Completion of Phase II Study of TRO40303
The study, a critical part of the EU funded MitoCare Project, will evaluate the reduction of reperfusion injury by TRO40303 in acute ST-elevation myocardial infarction (STEMI) patients.
Thursday, October 03, 2013
Trophos Launches First Study of Olesoxime in Multiple Sclerosis Patients
A Phase 1b study in RRMS patients is starting in three MS reference centers in France.
Tuesday, March 19, 2013
Trophos Announces Positive Interim Review in Pivotal Study of Olesoxime in SMA
Topline results expected in the fourth quarter of 2013.
Monday, March 04, 2013
Trophos Appoints JSB Partners as Global Partnership Advisor
Life science advisor to advise Trophos on strategic partnerships for orphan disease and niche indication candidates.
Monday, December 31, 2012
Marceline Clementine Appointed Chief Financial Officer
Ms. Clementine is now responsible for all administrative and financial services at Trophos.
Wednesday, September 19, 2012
Trophos Announces Conclusion of MitoTarget Consortium
EU funded 3-year project spearheaded by orphan disease specialist Trophos reports results from neurodegenerative program to the European Commission.
Wednesday, August 01, 2012
Trophos Appoints Christine Placet as Chief Executive Officer
Christine becomes CEO under a succession plan designed to provide continuity for Trophos.
Thursday, June 14, 2012
Trophos Announces Results of Phase III Study of Olesoxime in ALS
Company continues its ongoing programs and financed until at least the end of 2013.
Wednesday, December 14, 2011
Trophos Initiates Phase II Study for Novel Cardioprotective Compound, TRO40303, in Acute MI
European study being performed as part of Trophos-led, EU funded MitoCare project.
Tuesday, November 01, 2011
Trophos Completes Patient Enrolment in Pivotal Efficacy Study of Olesoxime in SMA
Topline results expected in second half of 2013.
Friday, September 09, 2011
Trophos Successfully Completes Phase 1 Study for Novel Cardioprotective Compound, TRO40303
Phase 2 proof-of-concept study in acute myocardial infarction planned for second half 2011 with MitoCare EU consortium.
Friday, February 25, 2011
Trophos to Lead new MitoCare Consortium Awarded EUR 6 Million to Study Cardioprotective Compound, TRO40303
Program of translational research to study innovative approaches to reducing cardiac ischemia-reperfusion injury.
Wednesday, December 15, 2010
Trophos Initiates Pivotal Efficacy Study of Olesoxime in Spinal Muscular Atrophy
European study supported by partnership with the Association Française contre les Myopathies.
Monday, October 18, 2010
Scientific News
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos